Porotto M, Greengard O, Poltoratskaia N, Horga M A, Moscona A
Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029, USA.
J Virol. 2001 Aug;75(16):7481-8. doi: 10.1128/JVI.75.16.7481-7488.2001.
The envelope of human parainfluenza virus type 3 (HPF3) contains two viral glycoproteins, the hemagglutinin-neuraminidase (HN) and the fusion protein (F). HN, which is responsible for receptor attachment and for promoting F-mediated fusion, also possesses neuraminidase (receptor-destroying) activity. We reported previously that 4-guanidino-neu5Ac2en (4-GU-DANA) and related sialic acid-based inhibitors of HPF3 neuraminidase activity also inhibit HN-mediated receptor binding and fusion processes not involving neuraminidase activity. We have now examined this mechanism, as well as neuraminidase's role in the viral life cycle, using a neuraminidase-deficient HPF3 variant (C28a) and stable cell lines expressing C28a or wild-type (wt) HN. C28a, which has a wt F sequence and two point mutations in the HN gene corresponding to two amino acid changes in the HN protein, is the first HPF3 variant with insignificant neuraminidase activity. Cells expressing C28a HN did not bind erythrocytes at 4 degrees C unless pretreated with neuraminidase, but no such pretreatment was required for hemadsorption activity (HAD) at 22 or 37 degrees C. HAD was blocked by 4-GU-DANA, attesting to the ability of this compound to inhibit HN's receptor-binding activity. C28a or wt plaque enlargement, a process that involves cell-cell fusion and does not depend on virion release, is diminished by the presence of 4-GU-DANA, confirming the inhibitory effect of 4-GU-DANA on the fusogenic function of C28a HN. In C28a-infected cell monolayers, virion release and thus multicycle replication are severely restricted. This defect was corrected by supplementation of exogenous neuraminidase and also by the addition of 4-GU-DANA; neuraminidase destroys the receptors whereby newly formed C28a virions would remain attached to the cell surface, whereas 4-GU-DANA prevents the attachment itself, obviating the need for receptor cleavage. In accord with the ability of 4-GU-DANA to prevent attachment, the neuraminidase inhibitory effect of 4-GU-DANA on wt HPF3 did not diminish virion release into the medium. Thus, it is by inhibition of viral entry and syncytium formation that sialic acid analogs like 4-GU-DANA may counteract wt HPF3 infection.
人副流感病毒3型(HPF3)的包膜包含两种病毒糖蛋白,即血凝素神经氨酸酶(HN)和融合蛋白(F)。HN负责受体附着并促进F介导的融合,同时还具有神经氨酸酶(受体破坏)活性。我们之前报道过,4-胍基-neu5Ac2en(4-GU-DANA)及相关的基于唾液酸的HPF3神经氨酸酶活性抑制剂也能抑制HN介导的受体结合和不涉及神经氨酸酶活性的融合过程。我们现在使用一种缺乏神经氨酸酶的HPF3变体(C28a)以及表达C28a或野生型(wt)HN的稳定细胞系,研究了这一机制以及神经氨酸酶在病毒生命周期中的作用。C28a具有野生型F序列,其HN基因中有两个点突变,对应于HN蛋白中的两个氨基酸变化,是首个神经氨酸酶活性不显著的HPF3变体。表达C28a HN的细胞在4℃时不结合红细胞,除非先用神经氨酸酶预处理,但在22℃或37℃时进行血细胞吸附活性(HAD)检测则无需这种预处理。HAD被4-GU-DANA阻断,证明该化合物能够抑制HN的受体结合活性。C28a或野生型噬斑扩大是一个涉及细胞-细胞融合且不依赖于病毒粒子释放的过程,4-GU-DANA的存在会使其减弱,这证实了4-GU-DANA对C28a HN融合功能的抑制作用。在感染C28a的细胞单层中,病毒粒子释放以及多轮复制受到严重限制。通过补充外源性神经氨酸酶以及添加4-GU-DANA可以纠正这一缺陷;神经氨酸酶会破坏受体,使新形成的C28a病毒粒子附着在细胞表面,而4-GU-DANA则阻止这种附着本身,从而无需受体裂解。与4-GU-DANA阻止附着的能力一致,4-GU-DANA对野生型HPF3的神经氨酸酶抑制作用并未减少病毒粒子释放到培养基中。因此,像4-GU-DANA这样的唾液酸类似物可能通过抑制病毒进入和多核体形成来对抗野生型HPF3感染。